IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
Good Shad reported acquisition or exercise transactions in this Form 4 filing.
IceCure Medical Ltd. reported that VP, Sales for North America Good Shad received a grant of 131,483 restricted share units (RSUs) on August 14, 2026. These RSUs vest 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter. Following this award, Shad holds a total of 136,698 ordinary share-based interests, comprising the new RSUs, 219 ordinary shares, and several prior RSU grants with similar 25%-then-quarterly vesting schedules, most of which remain unvested as of August 13, 2026. The figures reflect IceCure’s 1-for-30 reverse share split.
IceCure Medical Ltd. filed an initial Form 3 for director David Salton, reporting his status as a director of the company. This filing does not list any specific equity holdings or derivative positions and shows no reported transactions at this time.
Tel-Tzure Tlalit Bussi reported acquisition or exercise transactions in this Form 4 filing.
IceCure Medical Ltd. reported that officer Tel-Tzure Tlalit Bussi, VP, BD & Global Marketing, received a grant of 101,483 restricted share units (RSUs) on August 14, 2026. The RSUs vest over time: 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter. Following this award, Bussi’s directly held equity position, including existing ordinary shares and multiple prior RSU grants with similar quarterly vesting structures, is reported at 106,518 ordinary shares/RSUs. Except for the 25% tranche of RSUs granted July 2, 2024 that vested on July 29, 2026, all referenced RSUs remain unvested as of August 13, 2026. The holdings also reflect IceCure’s 1-for-30 reverse share split.
Levav Shay reported acquisition or exercise transactions in this Form 4 filing.
IceCure Medical Ltd. (ICCM) reported that Chief Operating Officer Levav Shay received a grant of 141,483 restricted share units (RSUs) on August 14, 2026, at a stated price of $0.00 per share. Twenty-five percent of this award vests on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25%. After this grant, Shay holds 146,303 RSUs in total, including earlier RSU awards from 2024–2026, most of which remain unvested as of August 13, 2026.
IceCure Medical Ltd. reported that executive Dotan Merav Nir, VP Human Resources, received a compensation-related equity award. On August 14, 2026 he was granted 73,890 restricted share units (RSUs) with no cash exercise price. Following this grant, his reported holdings total 76,168 ordinary shares and RSUs, consisting of the new award plus previously granted RSUs and 17 ordinary shares. The new 73,890-RSU grant vests 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter.
Peleg Meir reported acquisition or exercise transactions in this Form 4 filing.
IceCure Medical Ltd. reported that its Chief Financial Officer, Meir Peleg, received an equity compensation award. He was granted 181,483 restricted share units (RSUs) on August 14, 2026 at $0.00 per share-equivalent. According to the award terms, 25% of these RSUs vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter. The footnote also notes a prior grant of 13,333 RSUs on May 17, 2026 with the same 25%/75% quarterly vesting structure, and states that all of these RSUs remained unvested as of August 13, 2026. Following the new grant, Peleg’s reported holdings related to these awards total 194,816 ordinary share-equivalents, adjusted for a 1-for-30 reverse share split effected on June 4, 2026.
IceCure Medical Ltd. reported that director Chan Vincent Chun Hung ceased serving on the board on August 12, 2026. This exit Form 4 states that, following this departure, he is no longer subject to Section 16 reporting obligations for IceCure Medical Ltd., and it reports no insider transactions or holdings.
IceCure Medical Ltd. reports that its board of directors approved an increase in the ordinary shares reserved for its 2024 Employee Equity Incentive Plan. The reserve rose by 2,500,000 ordinary shares, from 112,667 to 2,612,667 ordinary shares available for future equity awards to employees.